Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

To give some idea of the sheer size of Johnson & Johnson, a glance at its reported sales figure is revealing. In the fourth ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $166 from $162 and keeps a Neutral rating on the ...

Q Earnings: $3.4 billion (-17%) FY Revenues: $88.8 billion (+4%) FY Earnings: $14.1 billion (+6%) Comments: Innovative Medicin ...

Guggenheim analyst Vamil Divan maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of ...